Defining the unknowns for cell therapies in Parkinson's disease.

ABSTRACT: First-in-human clinical trials have commenced to test the safety and efficacy of cell therapies for people with Parkinson's disease (PD). Proof of concept that this neural repair strategy is efficacious is based on decades of preclinical studies and clinical trials using primary foetal cells, as well as a significant literature exploring more novel stem cell-derived products. Although several measures of efficacy have been explored, including the successful in vitro differentiation of stem cells to dopamine neurons and consistent alleviation of motor dysfunction in rodent models, many unknowns still remain regarding the long-term clinical implications of this treatment strategy. Here, we consider some of these outstanding questions, including our understanding of the interaction between an

SUBMITTER: Lane EL 

PROVIDER: S-EPMC9555765 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature